The National Pharmaceutical Council (NPC) and Analysis Group recently partnered for a study on care pathways, and in it offered several recommendations to address key issues.
The study, “U.S. Care Pathways: Continued Focus on Oncology and Outstanding Challenges,” looked at “changes in development, implementation, and evaluation of care pathways.”
“The study found notable increases in process transparency, codification of standards, and prioritization of high-quality evidence, but additional improvements in transparency, including patient transparency, remain necessary,” an NPC blog post states.
To read more, click here.
